Affiliation:
1. From the Departments of Neurology (R.P.W.R., R.J.v.O., J.L.) and Internal Medicine, Division of Clinical and Experimental Immunology (J.D., J.W.C.T.), University Hospital Maastricht, The Netherlands.
Abstract
Background and Purpose—
Stroke is the leading cause of disability in the Western world; however, few therapies are at hand to decrease this burden.
Summary of Review—
Endothelial progenitor cells (EPCs) have been introduced in cardiovascular medicine as factotums. EPCs can repair damaged endothelium and attenuate the development and progression of atherosclerosis. Also, EPCs can form new vessels in ischemic areas and thus promote recovery after ischemic events. In stroke, however, EPC research is limited. In our overview, we provide background information on EPC use as a risk marker and as a potential therapeutic agent.
Conclusion—
In our opinion, the lack of EPC studies in stroke should instigate vascular neurologists to participate in EPC research, as EPCs could also change pathophysiological concepts and improve clinical treatments in vascular neurology.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialised Nursing,Cardiology and Cardiovascular Medicine,Clinical Neurology
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献